1. PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Leif W. Ellisen 
Cancer Cell 
Volume 19, Issue 2, Pages (February 2011)
DOI: /j.ccr
Copyright © 2011 Elsevier Inc. Terms and Conditions

2. Figure 1
PARP Inhibitor Treatment of BRCA1/2-Associated and Sporadic Cancers
Normal cells have intact base excision repair and homologous recombination that are mediated by PARP and BRCA1/2-dependent pathways, respectively. In germline BRCA1 or BRCA2 mutation carriers, the capacity for HR is often lost during tumorigenesis due to the inactivation of the remaining wild-type allele. PARP inhibitor treatment disables the repair of spontaneous DNA damage in these tumor cells, leading to their death. Sporadic tumors including triple-negative breast cancer may have defects in BRCA1/2 expression and/or function. Treatment combining a PARP inhibitor with DNA-damaging chemotherapy may be an effective strategy for some of these tumors. (Illustration courtesy of Zachary Nash.)
Cancer Cell  , DOI: ( /j.ccr )
Copyright © 2011 Elsevier Inc. Terms and Conditions